Chardan initiates Monopar stock with buy rating on Wilson disease drug

Monopar Therapeutics (MNPR) is navigating conflicting analyst sentiment, with Chardan Capital initiating 'Buy' coverage and a $60 price target, citing the potential of its late-stage Wilson disease drug ALXN1840 and early-stage radiopharmaceutical pipeline. This positive view is underpinned by ALXN1840's strong Phase III data and Monopar's plan for an early 2026 FDA filing, despite AstraZeneca's prior termination of the program. Conversely, Jones Trading downgraded MNPR to 'Hold' following Q4 results, citing fair valuation and the revised early 2026 NDA timeline as a delayed catalyst, tempering enthusiasm for a stock that has returned 852% over the past year and recently gained inclusion in Russell indexes.

Analysis

Monopar Therapeutics (MNPR) presents a high-risk, high-reward profile driven by conflicting analyst sentiment and a pivotal drug candidate with a complex history. Chardan Capital has initiated coverage with a 'Buy' rating and a $60 price target, citing potential in the late-stage Wilson disease treatment ALXN1840 and an early-stage radiopharmaceutical pipeline. This optimism is underpinned by robust Phase III data where ALXN1840 met its primary endpoint with statistical significance (p<0.001), demonstrating three times greater copper mobilization than standard care. However, this is sharply contrasted by the fact that the drug's previous owner, AstraZeneca, terminated the development program in 2023 due to concerns over earlier data and regulatory discussions, creating a significant overhang. The stock's formidable 852% return over the past year has prompted a valuation-based downgrade from Jones Trading to 'Hold', which views the stock as 'fairly valued' and considers the anticipated early 2026 New Drug Application filing a distant catalyst. Near-term, the company's inclusion in the Russell 3000 and 2000 indexes, effective June 27, 2025, is a positive development that could increase institutional ownership.

Key Decisions for Investors

• Investors must weigh the compelling and statistically significant Phase III efficacy data for ALXN1840 against the considerable regulatory risk highlighted by AstraZeneca's prior termination of the program.
• Considering the stock's 852% annual gain and the recent downgrade citing fair valuation, new positions should be approached with caution as the primary catalyst of an FDA filing is not expected until early 2026.
• Monitor the stock's performance around its upcoming inclusion in the Russell 2000 and 3000 indexes on June 27, 2025, which may create a short-term demand catalyst from passive funds.
• The investment thesis is a binary, long-term play on FDA approval, making any pre-submission updates or data releases from Monopar crucial events to watch for those holding or considering a position.